Immune Checkpoint Blockade Therapy Using 18F-FLT PET/CT

Summary

In the current study, advanced positron emission tomography/computed tomography (PET/CT) and positron emission tomography/magnetic resonance (PET/MR) imaging methods will be used to validate the hypothesis that participants receiving immune checkpoint blockade (ICB) therapy, who ultimately achieve clinical benefit, will show an increase, or "FLARE", in tumor FLT and/or FDG uptake from baseline, as seen after cycle#1 of treatment, and that after 2 cycles of treatment responders will have a decline in FLT and FDG uptake, in comparison to the participants classified as "non-responders".

Timeline

Start

2021-04-22

Primary completion

2025-01-31

Completion

2025-01-31

Outcome

Outcome not reported

Stopped (Enrollment): “Low accrual”

Drugs

Indications